Stentrode-based BCIs are a minimally-invasive neural interface technology where an electrode array is delivered to a brain blood vessel via a catheter, similar to a cardiac stent. The mechanism involves the stentrode expanding within the blood vessel, allowing its electrodes to record neural signals from the adjacent brain cortex without requiring open-brain surgery. Synchron, a US-based neurotechnology company, is the leading developer of this technology, alongside collaborative efforts with institutions like the University of Melbourne. This technology is in early commercialization, having advanced beyond initial feasibility studies to ongoing clinical trials in multiple countries. In July 2022, Synchron announced a patient with ALS used their Stentrode to tweet directly from his thoughts, demonstrating safe and effective long-term operation. This approach significantly reduces the risks associated with open-brain surgery required for traditional intracortical implants, offering a safer alternative with less recovery time.
Editorial check
How this page is checked
Source trail
synchron.com
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It Matters
This innovation could provide communication and motor control for millions globally suffering from paralysis (e.g., ALS, spinal cord injury, stroke), a patient population eager for less invasive solutions, potentially unlocking a multi-billion dollar market. Imagine paralyzed individuals recovering the ability to text, email, and control smart home devices simply by thinking, enabling greater independence and social connection from home. Synchron and other endovascular BCI developers will be major winners, while traditional invasive BCI companies might face pressure to match safety profiles. Regulatory approval for widespread clinical use, improving signal fidelity compared to direct cortical implants, and long-term vascular health implications are current barriers. Initial commercial availability for specific indications is expected within 3-7 years. The US and Australia are key players in advancing this minimally invasive approach. A second-order consequence could be the normalization of implantable brain interfaces as a routine medical procedure, similar to pacemakers, reducing the stigma associated with neurotechnology.
Development Stage
Related
Ratty – A terminal emulator with inline 3D graphics
Ratty is a cutting-edge terminal emulator that breaks the traditional 2D barrier by supporting inline 3D graphics. It allows applications running within the…
Retool
Retool is a low-code platform that allows you to build custom internal tools and applications quickly. You can drag and drop pre-built components like tables…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.